Aging
Navigate
Research Paper|Volume 16, Issue 2|pp 1111—1127

AMIGO2 is a pivotal therapeutic target related to M2 polarization of macrophages in pancreatic ductal adenocarcinoma

Shensi Chen1, Wujun Du2, Ke Feng2, Ke Liu2, Cunji Li2, Shengming Li2, Hua Yin3
  • 1Department of Gastrointestinal Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China
  • 2Department of Emergency, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China
  • 3Department of Gastroenterology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China
* Equal contribution and shares co-first authorship
Received: August 28, 2023Accepted: November 9, 2023Published: January 5, 2024

Copyright: © 2024 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a common kind of lethal cancer, with low early diagnostic rate and poor prognosis. In this study, we identified and verified the AMIGO2 with significant diagnostic and prognostic value in PDAC through LASSO regression combined with multiple machines learning methods, including RVM-RFE and Random Forest in TCGA and GEO datasets. The relevance between the expression of AMIGO2 and M2 polarization of macrophages was identified through pancancer, normal tissue, and cell lines data in TCGA, GTEx and CCLE datasets. The relevance between AMIGO2 and M2 polarization was then further identified in our local PDAC cohort. Finally, the role of AMIGO2 as cancer promoter and pivotal factor enrolled in M2 polarization was verified through siRNA transfection and M2 macrophages induction. These findings could facilitate diagnosis and treatment of PDAC. In addition, further research was deemed necessary on the deep mechanism between AMIGO2 and M2 polarization of macrophages in PDAC.